Authors:
Tokioka-Akagi, T
Fujimori, A
Shibasaki, M
Inagaki, O
Yanagisawa, I
Citation: T. Tokioka-akagi et al., Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload, JPN J PHARM, 86(1), 2001, pp. 79-85
Authors:
Ohmi, N
Wingfield, JM
Yazawa, H
Inagaki, O
Citation: N. Ohmi et al., Development of a homogeneous time-resolved fluorescence assay for high throughput screening to identify Lck inhibitors: Comparison with scintillationproximity assay and streptavidin-coated plate assay, J BIOMOL SC, 5(6), 2000, pp. 463-470
Authors:
Tokioka, T
Shibasaki, M
Fujimori, A
Matsuda-Satoh, Y
Uchida, W
Inagaki, O
Yanagisawa, I
Citation: T. Tokioka et al., Effects of YM358, an angiotensin II type 1 (AT(1)) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models, BIOL PHAR B, 23(2), 2000, pp. 174-181
Authors:
Yatsu, T
Tomura, Y
Tahara, A
Wada, K
Kusayama, T
Tsukada, J
Tokioka, T
Uchida, W
Inagaki, O
Iizumi, Y
Tanaka, A
Honda, K
Citation: T. Yatsu et al., Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V-1A and V-2 receptor antagonist, in dogs with pacing-induced congestive heart failure, EUR J PHARM, 376(3), 1999, pp. 239-246